Back to Search Start Over

Remote multiparametric monitoring and management of heart failure patients through cardiac implantable electronic devices.

Authors :
Boriani G
Imberti JF
Bonini N
Carriere C
Mei DA
Zecchin M
Piccinin F
Vitolo M
Sinagra G
Source :
European journal of internal medicine [Eur J Intern Med] 2023 Sep; Vol. 115, pp. 1-9. Date of Electronic Publication: 2023 Apr 17.
Publication Year :
2023

Abstract

In this review we focus on heart failure (HF) which, as known, is associated with a substantial risk of hospitalizations and adverse cardiovascular outcomes, including death. In recent years, systems to monitor cardiac function and patient parameters have been developed with the aim to detect subclinical pathophysiological changes that precede worsening HF. Several patient-specific parameters can be remotely monitored through cardiac implantable electronic devices (CIED) and can be combined in multiparametric scores predicting patients' risk of worsening HF with good sensitivity and moderate specificity. Early patient management at the time of pre-clinical alerts remotely transmitted by CIEDs to physicians might prevent hospitalizations. However, it is not clear yet which is the best diagnostic pathway for HF patients after a CIED alert, which kind of medications should be changed or escalated, and in which case in-hospital visits or in-hospital admissions are required. Finally, the specific role of healthcare professionals involved in HF patient management under remote monitoring is still matter of definition. We analyzed recent data on multiparametric monitoring of patients with HF through CIEDs. We provided practical insights on how to timely manage CIED alarms with the aim to prevent worsening HF. We also discussed the role of biomarkers and thoracic echo in this context, and potential organizational models including multidisciplinary teams for remote care of HF patients with CIEDs.<br />Competing Interests: Declaration of Competing Interest GB received small speaker's fees from Bayer, Boston, Boehringer, Daiichi Sankyo, Janssen and Sanofi, outside of the submitted work. The other authors declare no conflict of interest.<br /> (Copyright © 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0828
Volume :
115
Database :
MEDLINE
Journal :
European journal of internal medicine
Publication Type :
Academic Journal
Accession number :
37076404
Full Text :
https://doi.org/10.1016/j.ejim.2023.04.011